iA Global Asset Management Inc. Makes New Investment in CVS Health Corporation $CVS

iA Global Asset Management Inc. purchased a new stake in CVS Health Corporation (NYSE:CVS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 42,389 shares of the pharmacy operator’s stock, valued at approximately $3,364,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the period. Ares Financial Consulting LLC purchased a new position in CVS Health in the 4th quarter valued at approximately $29,000. Dogwood Wealth Management LLC boosted its position in CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 179 shares during the period. GoalVest Advisory LLC purchased a new position in CVS Health in the 4th quarter valued at approximately $32,000. Finally, Financial Consulate Inc. boosted its position in CVS Health by 99.6% in the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock valued at $40,000 after buying an additional 249 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $96.07 on Tuesday. The company’s fifty day moving average price is $79.06 and its 200 day moving average price is $78.66. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $98.43. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $122.58 billion, a P/E ratio of 42.32, a P/E/G ratio of 0.94 and a beta of 0.60.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the business earned $2.25 EPS. CVS Health’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Analysts Set New Price Targets

Several brokerages have commented on CVS. TD Cowen raised their price target on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Robert W. Baird raised their price objective on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, DA Davidson raised their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $98.08.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.